We have designed proprietary, patented delivery vehicles for vaccines, which can be administered either subcutaneously or intramuscularly. Our initial preclinical work has concentrated on developing peptide- and protein-based adjuvanted vaccines directed against modified sequences of the SARS-CoV-2 Spike protein. The first U.S. patent on these technologies (Patent #11911461) was issued on February 27, 2024.
containing our C.1.2 modified S1 sequence vaccine of the SARS-CoV-2 spike protein
Measurement Results
Sample Information
| Date/Time | 2/15/2024 |
|---|---|
| SampleID | C.1.2.MFLp 2yr |
| GroupID | SubATVax-C 021522 |
Graph of Results
Statistics
| Run | 1 | 2 | Avg | CV(%) |
|---|---|---|---|---|
| Mean (µm) | 0.8150 | 0.8141 | 0.8146 | 0.07813 |
| StDev (µm) | 0.4899 | 0.4890 | 0.4895 | 0.1300 |
| Total (%) | 100.0 | 100.0 | 100.0 | 0.0000 |
Laser sizing data of the above liposomes after two years stored at 4° Celsius
Our Vaccine
During the SARS-CoV-2 pandemic, we have developed polypeptide and baculovirus-expressed proteins containing the sequences of isolates C.1.2 (first isolated in South Africa), Omicron BA.1 (first isolated in South Africa), and Omicron BQ.1.1. The first two antigens have completed preclinical testing. A paper describing the C.1.2 subcutaneously administered vaccine was published in bioRxiv in September 2023. The U.S. patent on this work was issued on February 27, 2024. We recently completed two-year stability testing on this vaccine, stored at 4°C. Our adjuvanted vaccines are stored at 4°C unless colder temperatures are required for antigen stability.
